This SBIR Phase I award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $273,550 to Biocognon LLC for the development of a combinatorial platform to discover improved molecular recognition components for use in therapeutic and diagnostic antibodies. The project aims to utilize synthetic biology, next-generation DNA sequencing, and computational biology to efficiently generate and screen libraries of antibody recognition domains that can specifically bind to clinically important target antigens, such as a human receptor/ligand pair for cancer immunosuppression and a coronavirus surface protein. The platform is intended to expedite the design and discovery of current antibody-based therapeutics, as well as enable rapid development of new classes of therapeutics for personalized treatments and viral pandemics. The award period is from September 1, 2024 to August 31, 2025.
Generated 6/17/25, 3:51 AM